Magnetic Nanoclusters Armed with Responsive PD-1 Antibody Synergistically Improved Adoptive T-Cell Therapy for Solid Tumors
Source abstract
Abstract
Although adoptive T-cell therapy has been successful in hematological malignancy treatment, its application in solid tumors remains a great challenge. Here, using a pH-sensitive benzoic-imine bond and inverse electron-demand Diels-Alder cycloaddition, we prepared magnetic nanoclusters (NCs) armed with responsive PD-1 antibody (aP), which could then bind onto effector T cells due to their PD-1 expression. After adoptive transfer, the magnetization and superparamagnetism of NCs enabled us to magnetically recruit effector T cells and aP simultaneously to tumor sites with MRI guidance. Owing to the acidic intratumoral microenvironment, the benzoic-imine bond then hydrolyzed, leading to the release of aP. The therapeutic effects of adoptive T cells and free aP could thus be spatiotemporally coupled. As a result, we achieved inhibition of tumor growth with few side effects, demonstrating the great promise of such a chemical approach for safe and high-performance adoptive T-cell therapy against solid tumors.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Graphene and Nanomaterials Applications · CAR-T cell therapy research · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
School of Life Science, Beijing Institute of Technology, No. 5 South Street, Zhong Guan Cun, Beijing 100081, China
State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, 1 North Second Street, Zhong Guan Cun, Beijing 100190, China
Funding
National Natural Science Foundation of China · Ministry of Science and Technology of the People's Republic of China · Beijing Talents Fund
References (41)
Show source-provided references
1. 10.1038/nrc235510.1038/nrc2355 ↗
2. 10.1016/j.immuni.2013.07.00210.1016/j.immuni.2013.07.002 ↗
3. 10.1111/imr.1224310.1111/imr.12243 ↗
4. 10.1056/NEJMoa140722210.1056/NEJMoa1407222 ↗
5. 10.1016/j.coi.2018.04.00710.1016/j.coi.2018.04.007 ↗
6. 10.1038/nrclinonc.2011.11610.1038/nrclinonc.2011.116 ↗
7. 10.1158/0008-5472.CAN-14-245810.1158/0008-5472.CAN-14-2458 ↗
8. 10.1016/j.canlet.2015.10.00910.1016/j.canlet.2015.10.009 ↗
9. 10.1038/ncomms845810.1038/ncomms8458 ↗
10. 10.1158/1078-0432.CCR-14-277710.1158/1078-0432.CCR-14-2777 ↗
11. 10.1038/nrc324510.1038/nrc3245 ↗
12. 10.1111/j.1600-065X.2006.00442.x10.1111/j.1600-065X.2006.00442.x ↗
13. 10.1038/nri180610.1038/nri1806 ↗
14. 10.1016/j.cell.2008.05.00910.1016/j.cell.2008.05.009 ↗
15. 10.1038/nrc323910.1038/nrc3239 ↗
16. 10.1146/annurev.immunol.26.021607.09033110.1146/annurev.immunol.26.021607.090331 ↗
17. 10.1002/adfm.20180468810.1002/adfm.201804688 ↗
18. 10.1038/s41551-016-001110.1038/s41551-016-0011 ↗
19. 10.1126/scitranslmed.aan040110.1126/scitranslmed.aan0401 ↗
20. 10.1002/anie.20150079910.1002/anie.201500799 ↗
21. 10.1002/cncr.2240210.1002/cncr.22402 ↗
22. 10.1111/j.1476-5381.2009.00190.x10.1111/j.1476-5381.2009.00190.x ↗
23. 10.1038/nri276110.1038/nri2761 ↗
24. 10.1038/nrclinonc.2016.5810.1038/nrclinonc.2016.58 ↗
25. 10.1021/acs.accounts.8b0024210.1021/acs.accounts.8b00242 ↗
26. 10.1002/adfm.20170332610.1002/adfm.201703326 ↗
27. 10.1021/acsnano.7b0308810.1021/acsnano.7b03088 ↗
28. 10.1002/adfm.20160598510.1002/adfm.201605985 ↗
29. 10.1021/nn200333m10.1021/nn200333m ↗
30. 10.1021/nn202969210.1021/nn2029692 ↗
31. 10.1021/nn300536y10.1021/nn300536y ↗
32. 10.1111/j.1600-065X.2010.00923.x10.1111/j.1600-065X.2010.00923.x ↗
33. 10.1073/pnas.091517410710.1073/pnas.0915174107 ↗
34. 10.1158/0008-5472.CAN-12-410010.1158/0008-5472.CAN-12-4100 ↗
35. 10.1158/0008-5472.CAN-15-108210.1158/0008-5472.CAN-15-1082 ↗
36. 10.1158/1078-0432.CCR-15-107010.1158/1078-0432.CCR-15-1070 ↗
37. 10.1038/mt.2012.25210.1038/mt.2012.252 ↗
38. 10.1021/acsnano.7b0495510.1021/acsnano.7b04955 ↗
39. 10.1021/acsnano.7b0350710.1021/acsnano.7b03507 ↗
40. 10.1038/s41551-018-0262-610.1038/s41551-018-0262-6 ↗
41. 10.1021/acs.nanolett.8b0272010.1021/acs.nanolett.8b02720 ↗